ILE655VAL Genotyping Study of HER2 - Positive Breast Cancer of Patients from Padang - Indonesia With High Resolution Melting Technique

Dwi Wulandari, Azamris Azamris, Isna Nurhayati, M Ali Warisman, Bugi Ratno Budiarto, Desriani Desriani

Abstract


Transtuzumab has proven to be a great improvement in the treatment of HER2 + of breast cancer patients, but it is associated with relevant adverse cardiac events and with significantly elevated cost of treatment.  One of the risk factors for cardiotoxicity due to transtuzumab is the I655V HER2 polymorphism (GTC> ATC mutation) in which the allele mutant (Ile val or val / val) has a higher risk than the wild type (Ile/Ile). The detection of specific alleles is very important for therapeutic decision-making. In this study, our group have developed a HRM with EvaGreen dye method to discriminate specific allele of I655V HER2 (wild type, heterozygote mutant or homozygote mutant) in 66 frozen section samples of HER2+ of breast cancer patients. Our group reported the wild type is the most prevalent allele (77,27%), whereas heterozygous mutation is significantly present in this research (21,21%) and only 1,52% of sample detected as minor allele.  It showed that only one sample detected as a minor allele (val/val) and may have relatively low abundance in the population. This method has been compared with sanger sequencing and giving 100% of validity.


Keywords


Breast cancer, HER2, I655V, HRM, allele

Full Text:

PDF

References


Beauclair, S., Formento, P., Fischel, JL., Lescaut, W., Largillier, R., Chamorey, E., Hofman, P., Ferrero, JM., Pages, G., Milano, G. (2007). Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity. Ann Oncol.18:1335–41

Budiarto, BR., Harahap, WA, Desriani. (2016). Development of Sybr Green I-Based Melting Curve Method for HER2I655V Polymorphism Detection in Breast Cancer. Makara J. Health Res., 20(2): 29-34

Budiarto, BR, Desriani. (2016). Detection of HER2 gene polymorphism in breast cancer: PCR optimization study. Sci Pharm., 84:103-11.

Budiarto, BR., and Desriani. (2016). Dataset reporting detection of breast cancer-related HER2I655V polymorphism using allele-specific polymerase chain reaction. Data Brief. 9: 689–95.

Capper, RL., Jin, YK., Lundgren, PB., Peplow, LM., et al. (2015). Quantitative high resolution melting: two methods to determine SNP allele

Chambliss, AB., Resnick, M., Petrides, AK., Clarke, WA., Marzinke, MA. (2017). Rapid screening for targeted genetic variants via high-resolution melting curve analysis. Clin Chem Lab Med., 55(4):507-16

Dahabreh, IJ., Murray, S.(2011). Lack of replication for the association between HER2 I655V polymorphism and breast cancer risk: a systematic review and meta-analysis. Cancer Epidemiol. 35(6):503-9.

De Laurentiis, M., Cancello, G., Zinno, L. et al.(2005). Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology. Ann Oncol .16 (Suppl 4): iv7–iv13.

Desriani, Harahap, WA., and Besari, AY. (2016). Improved PCR-RFLP Method for Her-2 Ile655Val Breast Cancer Patients Detection . IJASEIT, Vol. 6 No. 2:205-9

Eliyatkın, N., Yalçın, E., Zengel, B., Aktaş, S., and Vardar, E., (2015). Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way. J Breast Health (2013). 11(2): 59–66.

Garritano, S., Gemignani ,F., Voegele, C., Nguyen-Dumont, T., Calvez-Kelm, FL., Silva, DD, et, al.( 2009). Determining the effectiveness of High Resolution Melting analysis for SNP genotyping and mutation scanning at the TP53 locus. BMC Genet, 10: 5

Giglio, S., Monis PT, Saint CP. (2003). Demonstration of preferential binding of SYBR Green I to specific DNA fragments in real-time multiplex PCR. Nucleic Acids Res. 31(22), e136.

Gonzalez-Bosquet, J., Calcei, J., Wei, JS., Garcia-Closas, M., Sherman, ME., et al. (2011). Detection of somatic mutations by high-resolution DNA melting (HRM) analysis in multiple cancers. PLoS One 6: e14522.

http://globocan.iarc.fr/Pages/fact_sheets_population.aspx (accessed October 4, 2017)

Klapper, LN., Kirschbaum, MH., Sela, M., Yarden ,Y. (2000). Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res., 77: 25-79.

Lee, SC., Hou, MF., Hsieh, PC, Wu, SH., Hou, LA., Ma, H.,¬¬ Tsai, SM., Tsai, LY. (2008). A case-control study of the HER2 Ile655Val polymorphism and risk of breast cancer in Taiwan. Clin Biochem. 41(3):121-5.

Lemieux, J., Diorio, C., Côté, M., Provencher, L., Barabé, F., Jacob, S. et al. (2013). Alcohol and HER2 polymorphisms as risk factor for cardiotoxicity in breast cancer treated with trastuzumab. Anticancer Res., 33: 2569–2576.

Li, Y-D., Chu, Z-Z., Liu, X-G., Jing, H-C., Liu, Y-G., and Hao, DY. (2010). A Cost-effective High-resolution Melting Approach using the EvaGreen Dye for DNA Polymorphism Detection and Genotyping in Plants. Journal of Integrative Plant Biology. 52 (12): 1036–1042.

Lu, S., Wang, Z., Liu, H., Hao, X. (2010). HER2 Ile655Val polymorphism contributes to breast cancer risk: evidence from 27 case-control studies. Breast Cancer Res Treat. 124(3):771-8

Millikan, RC., Hummer, AJ., Wolff, MS., Hishida, A., Begg, CB. (2005). HER2 codon 655 polymorphism and breast cancer: results from kin-cohort and case–control analyses. Breast Cancer Res Treat.89(3):309–12.

Nelson, SE., Gould, MN., Hampton, JM., Trentham-Dietz A. (2005). A case-control study of the HER2 Ile655Val polymorphism in relation to risk of invasive breast cancer. Breast Cancer Res 7:R357–R364

Neve, RM., Lane, HA., Hynes, NE. (2001). Review The role of overexpressed HER2 in transformation. Ann Oncol. 12 Suppl 1:S9-13.

Roca, L., Dieras, V., Roche, H., Lappartient, E., Kerbrat, P., Cany, L., Chieze, S., Canon, JL., Spielmann, M., Penault-Llorca, F., Martin, AL., Mesleard, C., Lemonnier, J., et al. (2013). Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS 04 trial. Breast Cancer Res Treat. 139:789–800

Siddig A, Mohamed AO, Kamal H, Awad S, Hassan AH, Zilahi E, Al-Haj M, Bernsen R, Adem A (2008) HER-2/neu Ile655Val polymorphism and the risk of breast cancer. Ann N Y Acad Sci 1138:84–94

Slamon, DJ., Clark, GM., Wong, SG., Levin, WJ., Ullrich, A., McGuire, WL. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 235(4785):177-82.

Sun, W., Li, J-j., Xiong, C., Zhao, B., and Chen, S-l. (2016). The Potential Power of Bar-HRM Technology in Herbal Medicine Identification . Front Plant Sci. 7: 367.

Sun, Z., Shi, Y., Shen, Y., Cao, L., Zhang, W., and Xiaoxiang. (2015). Analysis of different HER‐2 mutations in breast cancer progression and drug resistance. J Cell Mol Med. 19(12): 2691–2701.

Takano, K., Ogasahara, K., Fujii,S., and Yutani, K. (1995). Contribution of hydrophobic residues to the stability of human lysozyme: calorimetric studies and X-ray structural analysis of the five isoleucine to valine mutants. J. Mol. Biol., 254: 62–76.

Toomey, S., Madden, SF., Furney, SJ., Fan, Y., McCormack, M., Stapleton, C, et, al. (2016). The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer. Oncotarget.7(46): 75518–25

Viani, GA., Afonso, SL., Stefano, EJ., De ,Fendi ,LI., Soares FV. (2007). Review Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer. 7():153.

Xue, J., Jiang, Z., Qi, F, Lv, S., Zhang, S., Wang, T., Zhang, X. (2014). Risk of trastuzumab-related cardiotoxicity in early breast cancer patients: a prospective observational study. J Breast Cancer. 17(4):363-9.

Youlden, DR., Cramb, SM., Yip, CH., and Baade, PD.(2014). Incidence and mortality of female breast cancer in the Asia-Pacific region. Cancer Biol Med. 11(2): 101–115.




DOI: http://dx.doi.org/10.14203/ab.v21i2.310

Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 ANNALES BOGORIENSES

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Annales Bogorienses Indexed by :

     

  

 

 

Statistic Visitors